What is Roth Capital’s Estimate for CLRB FY2025 Earnings?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Roth Capital upped their FY2025 EPS estimates for shares of Cellectar Biosciences in a research note issued on Thursday, November 13th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn ($8.19) per share for the year, up from their prior estimate of ($9.06). Roth Capital has a “Buy” rating on the stock. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Cellectar Biosciences’ Q4 2025 earnings at ($1.19) EPS, FY2026 earnings at ($5.41) EPS, FY2027 earnings at ($5.30) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at $4.17 EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $390.00.

Cellectar Biosciences Stock Performance

Cellectar Biosciences stock opened at $3.07 on Monday. The firm has a market cap of $13.02 million, a price-to-earnings ratio of -0.15 and a beta of 0.56. Cellectar Biosciences has a 1 year low of $2.71 and a 1 year high of $52.78. The firm’s 50 day moving average price is $4.47 and its two-hundred day moving average price is $5.88.

Cellectar Biosciences (NASDAQ:CLRB) last released its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.91) by $0.50.

Institutional Investors Weigh In On Cellectar Biosciences

Institutional investors have recently made changes to their positions in the company. Riverview Capital Advisers LLC bought a new stake in shares of Cellectar Biosciences in the 2nd quarter valued at approximately $75,000. Sequoia Financial Advisors LLC bought a new stake in Cellectar Biosciences in the third quarter worth approximately $60,000. Dimensional Fund Advisors LP bought a new stake in Cellectar Biosciences in the third quarter worth approximately $73,000. Citadel Advisors LLC acquired a new position in shares of Cellectar Biosciences during the 3rd quarter worth $104,000. Finally, XTX Topco Ltd raised its holdings in shares of Cellectar Biosciences by 122.6% during the 1st quarter. XTX Topco Ltd now owns 104,323 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 57,447 shares in the last quarter. 16.41% of the stock is currently owned by institutional investors and hedge funds.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.